What is compounding?
Drug compounding is often regarded as the process of combining or mixing drugs to create a medication tailored to the needs of an individual patient.
The generic form of Vetmedin is Pimobendan.
Vetmedin is in limited supply. Orders placed will be shipped as product continues to come off backorder.
Brimonidine is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye.
Brimonidine Tartrate Ophthalmic Solution, 0.2% is indicated for lowering intraocular pressure inpatients with open-angle glaucoma or ocular hypertension. The IOP lowering efficacy of BrimonidineTartrate Ophthalmic Solution, 0.2% diminishes over time in some patients. This loss of effect appearswith a variable time of onset in each patient and should be closely monitored.
The recommended dose is one drop of Brimonidine tartrate ophthalmic solution, in the affected eye(s) three times daily, approximately 8 hours apart.
Brimonidine tartrate ophthalmic solution, may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.
Brimonidine Tartrate Ophthalmic Solution, is contraindicated in patients with hypersensitivity tobrimonidine tartrate or any component of this medication. It is also contraindicated in patients receivingmonoamine oxidase (MAO) inhibitor therapy.
No information is available on overdosage in humans. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.
Although Brimonidine Tartrate Ophthalmic Solution, had minimal effect on blood pressure ofpatients in clinical studies, caution should be exercised in treating patients with severe cardiovasculardisease.
Brimonidine Tartrate Ophthalmic Solution, has not been studied in patients with hepatic or renalimpairment; caution should be used in treating such patients.
Brimonidine Tartrate Ophthalmic Solution, should be used with caution in patients withdepression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension orthromboangiitis obliterans.
During the studies there was a loss of effect in some patients. The IOP-lowering efficacy observedwith Brimonidine Tartrate Ophthalmic Solution, during the first month of therapy may not alwaysreflect the long-term level of IOP reduction. Patients prescribed IOP-lowering medication should beroutinely monitored for IOP.
Keep out of the reach of children.Do not use if seal on the bottle is missing or broken. Rx only.
Store between 15°- 25°C (59°- 77°F).